21 Partners has signed an agreement to acquire Synerlab, a manufacturer of pharmaceuticals, in order to achieve a new phase of growth. Ardian, the current shareholder will reinvest alongside 21 Partners with a minority stake.Synerlab is a leading European contract manufacturing organization (CMO) number one in the (CMO), production of sterile liquid solutions without preservative agents. Moreover, the company has a strong positioning as a specialist in solid form drugs. Synerlab has a unique expertise in small- to medium-scale industrial production, affording the company a competitive edge as an ideal partner for generics and mid size pharmas. Synerlab’s client portfolio is also composed of some major international pharmaceutical group’s.21 Partners and Ardian will provide their combined expertise to support the ambitious growth strategy of the company, built on three levers: • Organic growth, supported by a specialization of pharmaceutical contracting and a broader development of manufacturing;• International expansion, including support for expansion of its clients and extension of business activities into new markets – already representing 40% of Synerlab sales;• Market consolidation, targeted build-up strategy in Europe with a particular focus on Germany, Italy, Spain and Poland.Pierre Banzet, CEO of Synerlab, comments: "The management team and I look forward to this partnership with 21 Partners and Ardian, which will allow us to write a new chapter of growth in the Synerlab story, leveraging on their experience and networks .“ Gerard Pluvinet, Founding Managing Partner of 21 Partners, comments: "We fully share the strategic vision of Pierre Banzet and his team. We will put our effort and expertise to the service of this ambitious development project on the European market".